Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash & Current Investments (2020 - 2025)

Oncology Institute (TOI) has disclosed Cash & Current Investments for 6 consecutive years, with $27.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 41.65% year-over-year to $27.7 million, compared with a TTM value of $27.7 million through Sep 2025, down 41.65%, and an annual FY2024 reading of $49.7 million, down 40.05% over the prior year.
  • Cash & Current Investments was $27.7 million for Q3 2025 at Oncology Institute, down from $30.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $115.2 million in Q4 2021 and bottomed at $11.5 million in Q3 2021.
  • Average Cash & Current Investments over 5 years is $56.1 million, with a median of $49.7 million recorded in 2024.
  • The sharpest move saw Cash & Current Investments soared 1820.21% in 2021, then plummeted 45.77% in 2024.
  • Year by year, Cash & Current Investments stood at $115.2 million in 2021, then tumbled by 35.92% to $73.8 million in 2022, then grew by 12.26% to $82.9 million in 2023, then tumbled by 40.05% to $49.7 million in 2024, then plummeted by 44.32% to $27.7 million in 2025.
  • Business Quant data shows Cash & Current Investments for TOI at $27.7 million in Q3 2025, $30.3 million in Q2 2025, and $39.7 million in Q1 2025.